Automatic Website Traffic RSS

Four red flag signs of silent killer disease one in three Brits at risk of having

Although it may not lead to any symptoms, “occasionally” people with NASH or fibrosis might experience four side effects. The NHS says you should see a GP “urgently” or call 111 if you have any of ... read more

Eating Meat Or Fish Increases Chances Of Liver Disease? Expert Answers Its Association With NAFLD

One concerning fact about untreated NAFLD is that it may also lead to many types of cancer liver cancer being the most obvious one ... read more

Boehringer signs $1.3B deal with RNA biotech Ochre Bio to team up against MASH

The German drugmaker is paying British biotech Ochre Bio $35 million in upfront and near-term research-based milestone payments to investigate “multiple targets” for chronic liver disease. Top of the ... read more

Lack of sleep could be a factor in a ‘silent epidemic,’ shares the same effects of alcoholism: expert

More than a third of adults fail to get the recommended seven to eight hours of sleep each night — and the scarcity of shuteye can have a surprising effect. read more

Easily missed red flags of 'silent killer' disease suffered by millions of people

Millions of people across the country are feared to have a disease known as a "silent killer" and has a number of symptoms which are easy to miss ... read more

World Liver Day 2024: Uncovering the key culprits behind rising cases of Non-Alcoholic Fatty Liver Disease

World Liver Day, observed annually on April 19th, raises awareness about liver health and the importance of prevention and early detection of liver di ... read more

First National Study to Assess the Prevalence of NAFLD to be Conducted by Federal Government

A first-ever national study to assess the prevalence of nonalcoholic fatty liver disease (NAFLD)* will be conducted by the Agency for Healthcare Research and Quality (AHRQ)**, in collaboration with ... read more

Providing Access to Rezdiffra for NASH and the Therapies to Come | AMCP 2024

The pipeline for NASH treatments is robust, with six therapies in phase 3 development. Speakers at the annual AMCP meeting discuss Rezdiffra, the first drug approved specifically for NASH, and how to ... read more

Boehringer Ingelheim teams with Ochre Bio on $1.3B deal to combat MASH

The deal represents an expansion of Boehringer Ingelheim’s investments in the CLD treatment space and scales Ochre Bio’s ambitions, specifically around MASH cirrhosis. read more

6 Stocks Positioned to Soar as Investors Focus on MASH

While there is a lot of potential in this name, the uncertain timing of the regulatory pathway makes this ideal for the patient investor looking more for a NASH cirrhosis play. The company is well ... read more

Can A Fatty Liver Disease Increase Your Risk Of Heart Disease? Read What An Expert Has To Say

With proper treatment an early stage of fatty liver disease may not cause much harm However if left unmanaged it may also impact your heart ... read more

6 Stocks Positioned to Soar as Investors Focus on MASH

Detailed price information for JP Morgan Chase & Company (JPM-N) from The Globe and Mail including charting and trades. read more